| Literature DB >> 28333133 |
Mar Álvarez1, Alba Sebastián-Martín1, Guillermo García-Marquina1, Luis Menéndez-Arias1.
Abstract
Nucleoside reverse transcriptase (RT) inhibitors constitute the backbone of current therapies against human immunodeficiency virus type 1 and type 2 (HIV-1 and HIV-2, respectively). However, mutational pathways leading to the development of nucleoside analogue resistance are different in both types of HIV. In HIV-2, resistance to all approved nucleoside analogues is conferred by the combination of RT substitutions K65R, Q151M and M184V. Nucleotide incorporation kinetic analyses of mutant and wild-type (WT) HIV-2 RTs show that the triple-mutant has decreased catalytic efficiency due to the presence of M184V. Although similar effects were previously reported for equivalent mutations in HIV-1 RT, the HIV-2 enzymes were catalytically less efficient. Interestingly, in highly divergent HIV-1 RTs, K65R confers several-fold increased accuracy of DNA synthesis. We have determined the intrinsic fidelity of DNA synthesis of WT HIV-2 RT and mutants K65R and K65R/Q151M/M184V. Our results show that those changes in HIV-2 RT have a relatively small impact on nucleotide selectivity. Furthermore, we found that there were less than two-fold differences in error rates obtained with forward mutation assays using mutant and WT HIV-2 RTs. A different conformation of the β3-β4 hairpin loop in HIV-1 and HIV-2 RTs could probably explain the differential effects of K65R.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28333133 PMCID: PMC5363063 DOI: 10.1038/srep44834
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Nucleotide concentration dependence for the incorporation of dTTP into the 31T/21P duplex DNA for wild-type (WT) and mutant HIV-2 RTs.
The continuous line represents the best fit of the data to the Michaelis-Menten equation.
Pre-steady-state kinetic constants for the incorporation of dTTP on a heteropolymeric template-primer by WT and mutant HIV-2 RTs.
| Enzyme | |||
|---|---|---|---|
| WT HIV-2 RT | 13.6 ± 1.6 | 42.2 ± 11.1 | 0.32 ± 0.09 |
| K65R HIV-2 RT | 16.0 ± 1.1 | 53.7 ± 9.1 | 0.30 ± 0.06 |
| Q151M HIV-2 RT | 50.8 ± 4.7 | 99.0 ± 21.2 | 0.51 ± 0.12 |
| M184V HIV-2 RT | 27.5 ± 5.9 | 164 ± 77 | 0.168 ± 0.087 |
| K65R/Q151M/M184V HIV-2 RT | 19.1 ± 2.4 | 210 ± 53 | 0.091 ± 0.025 |
| WT BH10 HIV-1 RT | 11.6 ± 0.5 | 13.4 ± 1.9 | 0.86 ± 0.13 |
The template-primer 31T/21P was used as the substrate. Mean values ± standard deviations are given for each enzyme. Assays were performed independently at least three times. Reported values for the WT BH10 HIV-1 RT were taken from Matamoros et al.44.
Figure 2Nucleotide concentration dependence on the first-order rates for dCTP, dGTP and dATP incorporation into the DNA/DNA 31/21-mer 31T/21P, obtained with WT and the mutant HIV-2 RTs K65R and K65R/Q151M/M184V.
The first-order rates of the nucleotide incorporation reaction (kobs) were plotted against the corresponding nucleotide concentration. The data were fitted to the Michaelis-Menten equation to obtain Kd and kpol values (best fit represented with a solid line).
Pre-steady-state kinetic parameters for misincorporation.
| Enzyme | Nucleotide | Misinsertion ratio ( | |||
|---|---|---|---|---|---|
| WT HIV-2 RT | dCTP | (3.4 ± 0.4) × 10−2 | 6597 ± 1508 | (5.2 ± 1.3) × 10−6 | (1.6 ± 0.6) × 10−5 |
| dGTP | (5.3 ± 0.4) × 10−2 | 2702 ± 654 | (2.0 ± 0.5) × 10−5 | (6.1 ± 2.4) × 10−5 | |
| dATP | (4.0 ± 0.4) × 10−3 | 2715 ± 753 | (1.5 ± 0.4) × 10−6 | (4.6 ± 1.9) × 10−6 | |
| K65R HIV-2 RT | dCTP | (8.0 ± 0.6) × 10−3 | 3562 ± 783 | (2.2 ± 0.5) × 10−6 | (7.5 ± 2.2) × 10−6 (2.1) |
| dGTP | (2.8 ± 0.2) × 10−2 | 1928 ± 542 | (1.5 ± 0.4) × 10−5 | (4.8 ± 1.7) × 10−5 (1.3) | |
| dATP | (1.0 ± 0.1) × 10−3 | 2980 ± 699 | (3.4 ± 0.8) × 10−7 | (1.1 ± 0.3) × 10−6 (4.1) | |
| K65R/Q151M/M184V HIV-2 RT | dCTP | (7.3 ± 0.6) × 10−3 | 4985 ± 927 | (1.5 ± 0.3) × 10−6 | (1.6 ± 0.5) × 10−5 (1.0) |
| dGTP | (2.3 ± 0.2) × 10−2 | 2400 ± 511 | (9.6 ± 2.1) × 10−6 | (1.1 ± 0.4) × 10−4 (0.6) | |
| dATP | (1.1 ± 0.1) × 10−3 | 1754 ± 277 | (6.5 ± 1.1) × 10−7 | (7.1 ± 2.3) × 10−6 (0.6) |
The template-primer 31T/21P was used as the substrate. Data shown are the mean values ± standard deviation. Each of the assays was performed independently at least three times.
afins = [kpol(incorrect)/Kd(incorrect)]/[kpol(correct)/Kd(correct)], where incorrect nucleotides were dCTP, dGTP or dATP, and the correct nucleotide was dTTP. Numbers between parentheses represent the relative increase of fidelity, as determined for each incorrect nucleotide as the ratio: fins (WT_HIV-2 RT)/fins (mutant RT).
Pre-steady-state kinetic parameters for mispair extension.
| Enzyme | Base pair at the 3′ enda | Mismatch extensión ratio ( | |||
|---|---|---|---|---|---|
| WT HIV-2 RT | G:T | 2.41c | >8000 | <2.4 × 10−4 | ndd |
| G:G | 0.12 ± 0.01 | 2023 ± 381 | (5.8 ± 1.2) × 10−5 | (1.8 ± 0.6) × 10−4 | |
| G:A | (3.1 ± 0.2) × 10−3 | 5885 ± 990 | (5.3 ± 1.0) × 10−7 | (1.6 ± 0.6) × 10−6 | |
| K65R HIV-2 RT | G:T | 0.27c | >8000 | <2.7 × 10−5 | nd |
| G:G | (1.5 ± 0.1) × 10−2 | 2758 ± 492 | (5.4 ± 1.0) × 10−6 | (1.8 ± 0.5) × 10−5 (9.8) | |
| G:A | <4.1 × 10−4 | >8000 | nd | nd | |
| K65R/Q151M/M184V HIV-2 RT | G:T | 0.27 ± 0.01 | 1299 ± 175 | (2.1 ± 0.3) × 10−4 | (2.3 ± 0.7) × 10−3 (0.3) |
| G:G | (3.0 ± 0.3) × 10−2 | 2542 ± 773 | (1.2 ± 0.4) × 10−5 | (1.3 ± 0.5) × 10−4 (1.4) | |
| G:A | (1.5 ± 0.1) × 10−3 | 2213 ± 302 | (6.8 ± 1.0) × 10−7 | (7.4 ± 2.3) × 10−6 (0.3) |
The template-primer 31T/21P was used as the substrate. Data shown are the mean values ± standard deviation. Each of the assays was performed independently at least three times.
aThe first base corresponds to the template and the second to the primer.
bfext = [kpol(mismatched)/Kd(mismatched)]/[kpol(matched)/Kd(matched)]. Numbers between parentheses represent the relative increase of fidelity, as determined for each mispair as the ratio: fext (WT_HIV-2 RT)/fext (mutant RT).
cIndicated values are observed catalytic rates (kobs) at 10 mM concentration of dTTP.
dnd, not determined.
Figure 3Nucleotide concentration dependence on the first-order rates for dTTP incorporation into DNA/DNA 31/21-mers with G:T, G:A and G:G mismatches at their 3′ end.
The first-order rates of the incorporation reaction (kobs), obtained with WT and mutant HIV-2 RTs (K65R and K65R/Q151M/M184V), were plotted against the corresponding nucleotide concentration. The data were fitted to the Michaelis-Menten equation to obtain Kd and kpol values (best fit represented with a solid line).
Accuracy of WT and mutant RTs in M13mp2 lacZα forward mutation assays.
| RT | Total plaques | Mutant plaques | Mutant frequencya |
|---|---|---|---|
| WT HIV-2 | 9660 | 120 | 0.01242 |
| K65R HIV-2 | 4750 | 56 | 0.01179 (1.1) |
| K65R/Q151M/M184V HIV-2 | 5142 | 53 | 0.01031 (1.2) |
| BH10 HIV-1 | 2915 | 58 | 0.01990 (0.6) |
aBackground frequencies in these assays were estimated to be less than one in 20,000 plaques40. Numbers between parentheses indicate the fold-increase in fidelity relative to the WT HIV-2 RT.
Summary of error rates for WT and mutant RTs, for various classes of mutations, based on M13mp2 DNA-dependent DNA synthesis reactions.
| Mutation type | WT HIV-2 (ROD) | K65R HIV-2 RT | K65R/Q151M/M184V HIV-2 RT | WT HIV-1 (BH10) | ||||
|---|---|---|---|---|---|---|---|---|
| Number of errors | Error rate | Number of errors | Error rate | Number of errors | Error rate | Number of errors | Error rate | |
| All classes | 137 | 1/10027 | 57 | 1/11850 | 54 | 1/13541 | 63 | 1/6580 |
| Base substitutions | 88 | 1/8233 | 28 | 1/12723 | 24 | 1/16069 | 54 | 1/4049 |
| Transitions | 21 (24%) | 1 (4%) | 5 (21%) | 14 (26%) | ||||
| Transversions | 67 (76%) | 27 (96%) | 19 (79%) | 40 (74%) | ||||
| Frameshifts | 49 | 1/17506 | 29 | 1/14545 | 30 | 1/15220 | 9 | 1/28761 |
| Insertions | 0 (0%) | 0 (0%) | 1 (3%) | 0 (0%) | ||||
| Deletions | 49 (100%) | 29 (100%) | 29 (97%) | 9 (100%) | ||||
| At runsa | 5 | 1/91577 | 2 | 1/112575 | 1 | 1/243731 | 2 | 1/69086 |
| At non-runs | 44 | 1/9089 | 27 | 1/7283 | 29 | 1/7341 | 7 | 1/17240 |
aA run is here defined as a row of three or more identical nucleotides.